Frequency and associated factors of hair loss among patients with inflammatory bowel disease

World J Gastroenterol. 2015 Jan 7;21(1):229-32. doi: 10.3748/wjg.v21.i1.229.

Abstract

Aim: To identify the frequency of hair loss among patients with inflammatory bowel disease (IBD) and associated clinical and disease related factors.

Methods: We performed a cross sectional study in a tertiary referral adult IBD clinic. Self-reported history and characteristics of hair loss as well as clinical and demographic information were collected. Data were analyzed using univariate and multivariate analyses.

Results: Two hundred and ten consecutive IBD patients were recruited; one hundred and fifty patients met predefined inclusion and exclusion criteria. Thirty-three percent of patients reported a history of hair loss. Age, gender, IBD type and disease duration were not associated with hair loss. Hair loss was reported less frequently among patients with use of mesalamine (54% vs 73%, P = 0.03) and anti-tumor necrosis factor medications (anti-TNF) (14% vs 40%, P = 0.001). In multivariate analyses adjusting for gender, IBD type and duration of disease, these associations with mesalamine and anti-TNF remained significant [(adjusted values for mesalamine (OR = 0.43, 95%CI: 0.19-0.86) and anti-TNFs (OR = 0.28, 95%CI: 0.08-0.98)].

Conclusion: Hair loss is common among patients with IBD. Mesalamine and anti-TNF medications were associated with lower odds of hair loss. Further studies are required to assess the mechanism of hair loss among patients with IBD.

Keywords: Alopecia; Crohn’s disease; Inflammatory bowel disease; Ulcerative colitis.

MeSH terms

  • Adult
  • Alopecia / diagnosis
  • Alopecia / epidemiology*
  • Alopecia / prevention & control
  • Anti-Inflammatory Agents / therapeutic use
  • Biological Products / therapeutic use
  • Chi-Square Distribution
  • Cross-Sectional Studies
  • Female
  • Humans
  • Inflammatory Bowel Diseases / diagnosis
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / epidemiology*
  • Inflammatory Bowel Diseases / immunology
  • Male
  • Mesalamine / therapeutic use
  • Multivariate Analysis
  • Odds Ratio
  • Protective Factors
  • Retrospective Studies
  • Risk Factors
  • Tertiary Care Centers
  • Texas / epidemiology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Biological Products
  • Tumor Necrosis Factor-alpha
  • Mesalamine